Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 73.64% | -188.88% | 65.48% | 9.72% | -1.65% |
| Total Depreciation and Amortization | -100.00% | -2.12% | -2.88% | 0.41% | -1.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -97.03% | 14,250.00% | -114.55% | -29.79% | 37.43% |
| Change in Net Operating Assets | -31.59% | 40.34% | -49.71% | 339.22% | -203.20% |
| Cash from Operations | -253.39% | 138.91% | 77.79% | 50.45% | -33.33% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -72.68% | -32.38% | -13.44% |
| Total Debt Repaid | 200.00% | -1.42% | -0.72% | 0.00% | 0.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 203.69% | -170.12% | -82.44% | -34.82% | -15.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 198.58% |
| Net Change in Cash | 61.04% | -143.50% | 229.20% | 59.71% | 42.47% |